4,901 trials
Advanced Solid Neoplasm
Primary: Part A: Change From Time-matched Baseline in Fridericia-corrected QT Interval (QTcF) After Pevonedistat Administration — 1.310; -2.231; 3.180; -0.639 milliseconds
Chronic Kidney Disease
Primary: Geometric Mean Ratio of Maximum Observed Plasma Peak Concentration (Cmax) for Verinurad — 13.30; 33.96; 26.09 ng/mL
Healthy
Primary: Period 1 and Period 2, Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) Within 1 Dosing Interval (AUC[0-tau]) of Ethinylestradiol (EE) — 966…
Malaria,Falciparum
Primary: Number and Severity of Adverse Events After TB31F Administration — 0; 1; 1; 0 Participants
Healthy
Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve of Tirzepatide From Time Zero to Infinity (AUC[0-∞]) — 112000; 111000; 106000 Hour * nanogram per…
Healthy
Primary: Urinary Excretion of Tirzepatide Radioactivity Over Time Expressed As A Percentage of the Total Radioactive Dose Administered — 49.56 Percentage of the total radioactive…
Hepatic Insufficiency
Primary: Pharmacokinetics (PK): Area Under The Drug Concentration-Time Curve From Zero To Infinity (AUC[0-∞]) of Tirzepatide — 84300; 102000; 82000; 77000 nanogram*hour per…
Healthy
Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Lasmiditan — 140; 123; 124 nanograms per milliliter (ng/mL)
Type 2 Diabetes Mellitus
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 Participants
Renal Insufficiency · End Stage Renal Disease
Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Tirzepatide From Time Zero to Tlast (AUC[0-tlast]) — 78400; 81900; 98300; 81200…
Birch Pollen Allergy
Primary: Treatment Emergent Adverse Events — 13; 3; 81; 2 number of adverse events per arm
Depression · HIV Infections · HIV-Associated Cognitive Motor Complex
Primary: Influx Constant (Ki) for 18F-FDOPA PET. — 0.01415; 0.01409; 0.01588; 0.01592 min-1
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Total Clamp Disposition Index (cDI) — 1.9; 1.1; 0.0 pmol*m-2*L*min-2*kg-1 — p=<0.001
Healthy
Primary: Maximum Safinamide Plasma Concentration (Cmax) — 411.5; 792.1; 465.0; 825.3 nanogram/milliliter (ng/mL)
Healthy Volunteers
Primary: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Last Quantifiable Concentration (AUC0-t) of Midazolam — 24.2; 50.7 Nanogram Hours per Milliliter…